A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies
The main purpose of this study is to evaluate the safety of ramucirumab plus MEDI4736 in participants with locally advanced and unresectable or metastatic gastrointestinal or thoracic malignancies including gastric or gastroesophageal junction (GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or hepatocellular carcinoma (HCC).
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Participant must have measurable metastatic disease or locally advanced and unresectable disease
Participant must be willing to provide tumor tissue for biomarker analysis
Participants Must Not:
Participant must not have known brain metastases
Participant must not have active or prior documented autoimmune disease within the past 24 months
Participant must not have HIV, AIDS-related illness, or a history of immunodeficiency
Participant with hepatitis B or hepatitis C infection may not be eligible depending on your tumor type
Lilly Trial Alerts
You will complete the questionnaire on another website.YesNo